Mireille Mpoudi-Etame

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Alexandra Calmy, Tamara Tovar-Sanchez, Charles Kouanfack et al. · The Lancet HIV · 2020 · 164 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon

Francis Atéba Ndongo, Emilande Guichet, Eric Mimbe et al. · Emerging infectious diseases · 2022 · 24 citations · Full text

Veterinary Medicine, Community Health, Infectious Diseases +7

Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices

Marie Ballif, Lorna Renner, Jean Claude Dusingize et al. · Journal of the Pediatric Infectious Diseases Society · 2014 · 19 citations · Full text

Public Health, Infectious Diseases, Pediatrics +17

Risks of metabolic syndrome in the ADVANCE and NAMSAL trials

Tamara Tovar-Sanchez, Mireille Mpoudi-Etame, Charles Kouanfack et al. · Frontiers in Reproductive Health · 2023 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

Marwân‐al‐Qays Bousmah, Marie Libérée Nishimwe, Tamara Tovar-Sanchez et al. · PharmacoEconomics · 2020 · 16 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17